Oncolytic Vaccinia Viruses and Recombinant Viruses and Methods of Use Thereof

Mon, 13 Apr 2026 02:31:19 +0000
Intellectual Property

The USPTO published patent application US20260097116A1 by ViroMissile, Inc. covering clonal strains of vaccinia virus engineered as oncolytic virus therapies for treating cancer. The application includes claims for recombinant vaccinia viruses with inactivating mutations and heterologous gene products, pharmaceutical compositions, and methods of use for anti-tumor therapy.